Cambridge Investment Research Advisors
DRNA

Cambridge Investment Research Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,098
Closed -$377K – 3255
2021
Q2 		$377K Buy
+10,098
New +$310K ﹤0.01% 2287

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cambridge Investment Research Advisors's DRNA Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 10,098 shares — an estimated $377K sold.

Cambridge Investment Research Advisors first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $377K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,098 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $377K.
  • Cambridge Investment Research Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $377K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.